लोड हो रहा है...
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
BACKGROUND: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). METHODS: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic prog...
में बचाया:
| में प्रकाशित: | BMC Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
BioMed Central
2019
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6518639/ https://ncbi.nlm.nih.gov/pubmed/31088401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5678-1 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|